Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Second-line Chemotherapy Combined With Endostatin for Recurrent/Metastatic Head and Neck Epithelial Tumors That Cannot be Re-irradiated or Re-operated After Fist-line Platinum-based Chemotherapy

NCT03989830 is registered in ClinicalTrials.gov with Sun Yan as lead sponsor.

NCT NCT03989830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03989830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Second-line Chemotherapy Combined With Endostatin for Recurrent/Metastatic Head and Neck Epithelial Tumors That Cannot be Re-irradiated or Re-operated After Fist-line Platinum-based Chemotherapy
Lead sponsor
Sun Yan
Phase
Phase 2
Overall status
Unknown status
Start date
July 29, 2019
Completion date
June 30, 2022
Enrollment
53 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck neoplasms